Advancements in nano-enabled therapeutics for neuroHIV management

References

• NairMJayantRDKaushikASagarVGetting into the brain: potential of nanotechnology in the management of neuroAIDSAdv Drug Deliv Rev2016103120221726944096
   PubMedGoogle Scholar
• RuizANairMKaushikARecent update in NanoCure of neuroAIDSSci Lett J20154172
   Google Scholar
• ZhangYYinCZhangTCRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirsSci Rep201551627726538064
   PubMed Web of Science ®Google Scholar
• JayantRDAtluriVSAgudeloMSagarVKaushikANairMSustained-release nanoART formulation for the treatment of neuroAIDSInt J Nanomedicine2015101077109325709433
   PubMed Web of Science ®Google Scholar
• KellySGNyakuANTaiwoBOTwo-drug treatment approaches in HIV: finally getting somewhere?Drugs201676552353126886135
   PubMed Web of Science ®Google Scholar
• OwenARannardSStrengths, weaknesses, opportunities and challenges for long acting injectable therapies: insights for applications in HIV therapyAdv Drug Deliv Rev Epub2016223
   PubMed Web of Science ®Google Scholar
• TrezzaCFordSLSpreenWPanRPiscitelliSFormulation and pharmacology of long-acting cabotegravirCurr Opin HIV AIDS201510423924526049948
   PubMed Web of Science ®Google Scholar
• JacksonAGElseLJMesquitaPMA compartmental pharmacokinetic evaluation of long-acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxisClin Pharmacol Ther201496331432324862215
   PubMed Web of Science ®Google Scholar
• VerloesRDeleuSNiemeijerNCrauwelsHMeyvischPWilliamsPSafety, tolerability and pharmacokinetics of rilpivirine following administration of a long-acting formulation in healthy volunteersHIV Med201516847748425988676
   PubMed Web of Science ®Google Scholar
• MargolisDABrinsonCCSmithGHCabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trialLancet Infect Dis201515101145115526201299
   PubMed Web of Science ®Google Scholar
• GautamRNishimuraYPeguAA single injection of anti-HIV-1 antibodies protects against repeated SHIV challengesNature2016533760110510927120156
   PubMed Web of Science ®Google Scholar
• HuWKaminskiRYangFRNA-directed gene editing specifically eradicates latent and prevents new HIV-1 infectionProc Natl Acad Sci U S A201411131114611146625049410
   PubMed Web of Science ®Google Scholar
• KaminskiRChenYFischerTElimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editingSci Rep201662255526939770
   PubMed Web of Science ®Google Scholar
• JayantRDSosaDKaushikACurrent status of non-viral gene therapy for CNS disordersExpert Opin Drug Deliv Epub201661
   Web of Science ®Google Scholar
• PeluffoHUnzuetaUNegro-DemontelMLBBB-targeting, protein-based nanomedicines for drug and nucleic acid delivery to the CNSBiotechnol Adv201533227728725698504
   PubMed Web of Science ®Google Scholar
• RaoKSReddyMKHorningJLLabhasetwarVTAT-conjugated nanoparticles for the CNS delivery of anti-HIV drugsBiomaterials200829334429443818760470
   PubMed Web of Science ®Google Scholar
• MeadBMastorakosPSukJSSongJHanesJPriceRLocalized delivery of non-viral gene-bearing nanoparticles into the rat brain following focused ultrasound-mediated BBB openingJ Ther Ultrasound20153suppl 129
   Google Scholar
• MayerCRGeisNAKatusHABekeredjianRUltrasound targeted microbubble destruction for drug and gene deliveryExpert Opin Drug Deliv20085101121113818817517
   PubMed Web of Science ®Google Scholar
• TabatabaeiSNGirouardHCarretA-SMartelSRemote control of the permeability of the blood–brain barrier by magnetic heating of nanoparticles: a proof of concept for brain drug deliveryJ Control Release2015206495725724273
   PubMed Web of Science ®Google Scholar
• KaushikAJayantRDNikkhah-MoshaieRMagnetically guided central nervous system delivery and toxicity evaluation of magneto-electric nanocarriersSci Rep201662530927143580
   PubMed Web of Science ®Google Scholar
• KaushikAJayantRDSagarVNairMThe potential of magneto-electric nanocarriers for drug deliveryExpert Opin Drug Deliv201411101635164624986772
   PubMed Web of Science ®Google Scholar
• RoyURodríguezJBarberPdas NevesJSarmentoBNairMThe potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsNanomedicine201510243597360926400459
   PubMed Web of Science ®Google Scholar
• CarsonDJiangYWoodrowKATunable release of multiclass anti-HIV drugs that are water-soluble and loaded at high drug content in polyester blended electrospun fibersPharm Res201633112513626286184
   PubMed Web of Science ®Google Scholar
• DestacheCJMandalSZheYTopical tenofovir disoproxil fumarate (DF) nanoparticles prevents HIV-1 vaginal transmission in the humanized mouse modelAntimicrob Agents Chemother20166063633363927044548
   PubMed Web of Science ®Google Scholar
• FreelingJPKoehnJShuCSunJHoRJLong-acting three-drug combination anti-HIV nanoparticles enhance drug exposure in primate plasma and cells within lymph nodes and bloodAIDS201428172625262725102089
   PubMed Web of Science ®Google Scholar
• RoyUDingHPilakka-KanthikeelSPreparation and characterization of anti-HIV nanodrug targeted to microfold cell of gut-associated lymphoid tissueInt J Nanomed20151058195835
   PubMed Web of Science ®Google Scholar
• KovarovaMCouncilODDateAANanoformulations of rilpivirine for topical pericoital and systemic coitus-independent administration efficiently prevent HIV transmissionPLoS Pathog2015118e100507526271040
   PubMed Web of Science ®Google Scholar
• RaymondADiazPChevelonSMicroglia-derived HIV Nef+ exosome impairment of the blood–brain barrier is treatable by nanomedicine-based delivery of Nef peptidesJ Neurovirol20152212913926631079
   PubMed Web of Science ®Google Scholar
• NairMGuduruRLiangPHongJSagarVKhizroevSExternally controlled on-demand release of anti-HIV drug using magneto-electric nanoparticles as carriersNat Commun20134170723591874
   PubMed Web of Science ®Google Scholar
• AtluriSVJayantDRPilakka-KanthikeelSDevelopment of tissue inhibitor of metalloproteinase-1 (TIMP-1) magnetic nanoformulation for regulation of synaptic plasticity in HIV-1 infectionInt J Nanomedicine In Press2016
   Web of Science ®Google Scholar
• SenanayakeTHGorantlaSMakarovELuYWarrenGVinogradovSVNanogel-conjugated reverse transcriptase inhibitors and their combinations as novel antiviral agents with increased efficacy against HIV-1 infectionMol Pharm201512124226423626565115
   PubMedGoogle Scholar
• DalpiazAFogagnoloMFerraroLNasal chitosan microparticles target a zidovudine prodrug to brain HIV sanctuariesAntiviral Res201512314615726427553
   PubMed Web of Science ®Google Scholar
• SagarVPilakka-KanthikeelSAtluriVSTherapeutical neurotargeting via magnetic nanocarrier: implications to opiate-induced neuropathogenesis and neuroAIDSJ Biomed Nanotechnol201511101722173326502636
   PubMed Web of Science ®Google Scholar
• JayantRNairMRole of biosensing technology for neuroAIDS managementJ Biosens Bioelectron201671e14127280058
   PubMedGoogle Scholar
• KaushikAYndartAJayantRDElectrochemical sensing method for point-of-care cortisol detection in human immunodeficiency virus-infected patientsInt J Nanomedicine20151067768525632229
   PubMed Web of Science ®Google Scholar
• ShafieeHWangSInciFEmerging technologies for point-of-care management of HIV infectionAnnu Rev Med20156638740525423597
   PubMed Web of Science ®Google Scholar
• YagerPDomingoGJGerdesJPoint-of-care diagnostics for global healthAnnu Rev Biomed Eng20081010714418358075
   PubMed Web of Science ®Google Scholar
• KaushikATiwariSJayantRDMartyANairMTowards detection and diagnosis of Ebola virus disease at point-of-careBiosens Bioelectron20167525427226319169
   PubMed Web of Science ®Google Scholar
• KaushikAVasudevAAryaSKPashaSKBhansaliSRecent advances in cortisol sensing technologies for point-of-care applicationBiosens Bioelectron20145349951224212052
   PubMed Web of Science ®Google Scholar
• KaushikAJayantRDTiwariSVashistANairMNano-biosensors to detect beta-amyloid for Alzheimer’s disease managementBiosens Bioelectron20168027328726851586
   PubMed Web of Science ®Google Scholar
• CruzAFDNorenaNKaushikABhansaliSA low-cost miniaturized potentiostat for point-of-care diagnosisBiosens Bioelectron20146224925425016332
   PubMed Web of Science ®Google Scholar
• InciFTokelOWangSNanoplasmonic quantitative detection of intact viruses from unprocessed whole bloodACS Nano2013764733474523688050
   PubMed Web of Science ®Google Scholar
• ShafieeHLidstoneEAJahangirMNanostructured optical photonic crystal biosensor for HIV viral load measurementSci Rep20144411624576941
   PubMed Web of Science ®Google Scholar
• ChengXLiuY-SIrimiaDCell detection and counting through cell lysate impedance spectroscopy in microfluidic devicesLab Chip20077674675517538717
   PubMed Web of Science ®Google Scholar
• HolmesDMorganHSingle cell impedance cytometry for identification and counting of CD4 T-cells in human blood using impedance labelsAnal Chem20108241455146120104894
   PubMed Web of Science ®Google Scholar
• ShafieeHJahangirMInciFAcute on-chip HIV detection through label-free electrical sensing of viral nano-lysateSmall20139152553256323447456
   PubMed Web of Science ®Google Scholar
• WatkinsNNSridharSChengXA microfabricated electrical differential counter for the selective enumeration of CD4+ T lymphocytesLab Chip20111181437144721283908
   PubMed Web of Science ®Google Scholar
• KaushikAVabbinaPKAtluriVElectrochemical monitoring-on-chip (E-MoC) of HIV-infection in presence of cocaine and therapeuticsBiosens Bioelectron20168642643127419908
   PubMed Web of Science ®Google Scholar